Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Gaetano Bonifacio"'
Publikováno v:
IpoTESI di Preistoria, Vol 13, Iss 1, Pp 37-52 (2020)
Preliminary archaeological investigations between Naples and Cancello on the Naples-Bari railway track in October 2014, brought a necropolis to the light that can be dated between the Late Copper Age and the Early Bronze Age. The archeological invest
Externí odkaz:
https://doaj.org/article/9adea6161cb646208a4232315251eea5
Autor:
Eytan M. Stein, Min Yang, Annie Guerin, Wei Gao, Philip Galebach, Cheryl Q. Xiang, Subrata Bhattacharyya, Gaetano Bonifacio, George J. Joseph
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background Preference valuations of health status are essential in health technology and economic appraisal. This study estimated utilities for treatment-related health states of acute myeloid leukemia (AML) and disutilities of severe advers
Externí odkaz:
https://doaj.org/article/d237ba30b31c4c1a8cd41e5c026b90bd
Autor:
Amer M. Zeidan, Daniel A. Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Thomas Prebet, Maria Strocchia, Gaetano Bonifacio, Clara Chen
Publikováno v:
Annals of Hematology. 102:749-754
Autor:
Eric Q. Wu, Annie Guerin, Dominick Latremouille-Viau, Xiting Cao, Sherry Shi, Gaetano Bonifacio, Islam Sadek, Eytan M. Stein
Publikováno v:
Journal of Medical Economics. 24:234-243
Aims To describe healthcare resource utilization (HRU) and costs in patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA) based on HMA-treatment response. Materials and methods SEER-Medicare data (January 2006-Decemb
Autor:
Abhinav Deol, Scott D. Rowley, Mrinal M. Patnaik, Mark Levis, Hugo F. Fernandez, Richard T. Maziarz, Gaetano Bonifacio, Kelly Haines, Bart L. Scott, Sanjay R. Mohan, Das Purkayastha, Daniela Hernandez, Trivikram Rajkhowa, Patrice Rine, Dennis Dong Hwan Kim
Publikováno v:
Bone Marrow Transplantation
We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with acute myeloid leukemia (AML) harboring internal tandem duplication (ITD)
Autor:
Mark R. Litzow, Stephen A. Strickland, Kelly Haines, Gaetano Bonifacio, Andrew Dalovisio, Alysha Barbera, Gail J. Roboz, Alexander E. Perl, Kendra Sweet, Das Purkayastha
Publikováno v:
Leukemia & Lymphoma. 61:3146-3153
Approval of midostaurin, a multikinase inhibitor, in combination with chemotherapy for the treatment of adults with newly diagnosed FLT3 mutation–positive acute myeloid leukemia, was based on the p...
Autor:
Eric Q. Wu, Gaetano Bonifacio, Annie Guerin, Xiting Cao, George J Joseph, Dominick Latremouille-Viau, Eytan M. Stein, Sherry Shi
Publikováno v:
Leukemialymphoma. 62(6)
Background: Hypomethylating agents (HMA), azacitidine (AZA) and decitabine (DEC), are the current standard of care in patients with intermediate-2 and high risk myelodysplastic syndromes (MDS) by IPSS prognostic category (higher-risk MDS) based on cl
Autor:
Gail J, Roboz, Stephen A, Strickland, Mark R, Litzow, Andrew, Dalovisio, Alexander E, Perl, Gaetano, Bonifacio, Kelly, Haines, Alysha, Barbera, Das, Purkayastha, Kendra, Sweet
Publikováno v:
Leukemialymphoma. 61(13)
Approval of midostaurin, a multikinase inhibitor, in combination with chemotherapy for the treatment of adults with newly diagnosed
Autor:
Dominick Latremouille-Viau, Eytan M. Stein, Sherry Shi, George J Joseph, Annie Guerin, Patrick Gagnon-Sanschagrin, Owanate Briggs, Gaetano Bonifacio
Publikováno v:
Journal of Medical Economics. 21:556-563
Objective: To describe the setting, duration, and costs of induction and consolidation chemotherapy for adults with newly-diagnosed acute myeloid leukemia (AML), who are candidates for standard induction chemotherapy, in the US. Methods: Adults newly
Autor:
Daniel A. Pollyea, Alberto Vasconcelos, Ravi Potluri, Lona Gaugler, David Rotter, Zephirin Kiendrebeogo, Gaetano Bonifacio, Clara Chen, Uma Borate, Amer M. Zeidan
Publikováno v:
Blood. 138:277-277
INTRODUCTION : Many patients (pts) with newly diagnosed (ND) AML achieve remission with IC regimens, typically comprising cytarabine and an anthracycline, with the eventual goal of therapy being cure. On 21 Nov 2018, the FDA approved venetoclax (VEN)